Compare Ginkgo Bioworks Holdings Inc (DNA) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs MGM Resorts International — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while MGM Resorts International trades at $46.89 (market cap $11.94B). The key difference: MGM Resorts International is far larger — about 20.2× Ginkgo Bioworks Holdings Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MGM | |
|---|---|---|
Market Cap | $590.53M | $11.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $50.69 |
52-Week Low | $5.48 | $30.72 |
Enterprise Value | $627.78M | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
MGM Resorts International (MGM) trades at $47.24, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent financials show revenue growth to $17.54B in 2025, though net income margin remains thin at 1.03%. The stock is buoyed by acquisition talks with Barry Diller's People Inc. at $48.30 per share, as reported by The Wall Street Journal on July 10, 2026, and positive cash flow projections for 2026.
Outlook: MGM offers moderate upside potential driven by acquisition interest and steady revenue, but risks include volatile earnings, high debt, and regulatory scrutiny. Investors should weigh the takeover premium against fundamental weakness in profitability and execution risks in the competitive casino sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
